In: Commentaries

Archimedes‘ fulcrum and the “reproducibility” debate
June 16, 2022

We like to cite Dorothy Bishop who wrote several years ago: “We know how to formulate and test hypotheses in controlled…

Read More
“Serial de-risking”: Quod licet Iovi non licet bovi?
June 16, 2022

When it comes to novel therapies, positive data has justifiably more value than negative or null data.  Indeed, positive data promises…

Read More
Pre-study odds
March 14, 2022

One of the key themes in the 2005 seminal paper by John Ioannidis “Why most published research findings are false” is…

Read More
Preparing for a journey
February 27, 2022

Recently, I went on a trip to a nice hotel with a swimming pool. Upon arrival, standing in the modern room…

Read More
The “from-quality-to-system” pendulum
December 20, 2021

by Anton Bespalov and Anja Gilis In the dialectics world of the German philosopher Georg Hegel, quantitative changes transform into qualitative…

Read More
Of peer review and data sharing
November 3, 2021

 We (preclinical) learn from the Big Brother (clinical). For example, they recognize the risks of bias in study design, conduct and…

Read More
“Don’t cut the tree you are sitting on!”
November 3, 2021

According to a recent press release from the European parliament, an EU-wide action plan is requested with ambitious and achievable objectives for phasing-out…

Read More
How to See More Clearly in the Lab?
June 16, 2021

When you can see the world clearly, it’s easy to get where you want to go: You might still get where…

Read More
Aducanumab’s approval is not FDA’s failure, it is our failure
June 16, 2021

On June 7, 2021, the FDA approved aducanumab, an amyloid beta-directed monoclonal antibody indicated for the treatment of Alzheimer’s disease.However, most…

Read More
Pseudoreplication in Physiology – more means less
March 30, 2021

Many publications leave it to readers to guess whether reported data are based on independent biological replicates (e.g. number of animals)…

Read More